Acrigen Biosciences
Biotechnology, 1000 Atlantic Ave, Alameda, California, 94501, United States, 1-10 Employees
Phone Number: +15*********
Who is ACRIGEN BIOSCIENCES
Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprie...
Read More
-
Headquarters: 1000 Atlantic Ave, Alameda, California, 94501, United States
-
Date Founded: 2019
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ACRIGEN BIOSCIENCES
Acrigen Biosciences Org Chart and Mapping
Email
Phone
Similar Companies to Acrigen Biosciences
Berkeley Yeast
-
11-50
-
$ 5 Million to 10 Million
Juvena Therapeutics
-
11-50
-
$ 1 Million to 5 Million
Mammoth Biosciences
-
51-200
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Acrigen Biosciences
Answer: Acrigen Biosciences's headquarters are located at 1000 Atlantic Ave, Alameda, California, 94501, United States
Answer: Acrigen Biosciences's phone number is +15*********
Answer: Acrigen Biosciences's official website is https://acrigen.com
Answer: Acrigen Biosciences's revenue is $1 Million to $5 Million
Answer: Acrigen Biosciences's SIC: 2836
Answer: Acrigen Biosciences's NAICS: 541714
Answer: Acrigen Biosciences has 1-10 employees
Answer: Acrigen Biosciences is in Biotechnology
Answer: Acrigen Biosciences top competitors include: Berkeley Yeast , Juvena Therapeutics , Mammoth Biosciences
Answer: Acrigen Biosciences contact info: Phone number: +15********* Website: https://acrigen.com
Answer: Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month